DexCom Inc. (DXCM) Insider Sells $300,499.60 in Stock
DexCom Inc. (NASDAQ:DXCM) insider John Lister sold 3,560 shares of the stock in a transaction dated Monday, October 10th. The shares were sold at an average price of $84.41, for a total transaction of $300,499.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
John Lister also recently made the following trade(s):
- On Friday, September 9th, John Lister sold 3,560 shares of DexCom stock. The shares were sold at an average price of $93.65, for a total transaction of $333,394.00.
DexCom Inc. (NASDAQ:DXCM) traded up 0.16% during mid-day trading on Wednesday, hitting $82.02. 440,524 shares of the stock were exchanged. DexCom Inc. has a 12-month low of $47.92 and a 12-month high of $96.38. The stock’s market capitalization is $6.88 billion. The firm has a 50-day moving average price of $90.14 and a 200-day moving average price of $78.37.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/12/dexcom-inc-dxcm-insider-sells-300499-60-in-stock.html
DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Tuesday, August 2nd. The medical device company reported ($0.24) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.12) by $0.12. The firm earned $137.30 million during the quarter, compared to analyst estimates of $132.48 million. DexCom had a negative return on equity of 19.68% and a negative net margin of 16.42%. DexCom’s revenue for the quarter was up 47.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.05) earnings per share. Equities analysts predict that DexCom Inc. will post ($0.57) earnings per share for the current fiscal year.
A number of brokerages recently issued reports on DXCM. B. Riley began coverage on shares of DexCom in a research report on Monday, September 26th. They issued a “neutral” rating and a $97.00 target price for the company. Jefferies Group reiterated a “buy” rating and issued a $98.00 target price on shares of DexCom in a research report on Wednesday, August 3rd. Benchmark Co. reduced their price objective on shares of DexCom from $106.00 to $86.00 and set a “buy” rating for the company in a research report on Wednesday, August 3rd. BMO Capital Markets started coverage on shares of DexCom in a research report on Friday, September 16th. They set an “outperform” rating and a $112.00 price objective for the company. Finally, Desjardins upgraded shares of DexCom from a “hold” rating to a “buy” rating in a research report on Friday, September 16th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $95.08.
A number of hedge funds have recently made changes to their positions in the company. BNP Paribas Arbitrage SA raised its stake in shares of DexCom by 3,320.0% in the third quarter. BNP Paribas Arbitrage SA now owns 1,197 shares of the medical device company’s stock worth $105,000 after buying an additional 1,162 shares during the last quarter. Bellwether Investment Group LLC purchased a new stake in shares of DexCom during the second quarter worth approximately $119,000. Bank of Montreal Can purchased a new stake in shares of DexCom during the second quarter worth approximately $134,000. Capstone Asset Management Co. purchased a new stake in shares of DexCom during the third quarter worth approximately $205,000. Finally, CIBC Asset Management Inc purchased a new stake in shares of DexCom during the second quarter worth approximately $211,000. Hedge funds and other institutional investors own 99.37% of the company’s stock.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.
Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.